Novo Nordisk Adopts 'Novo' Name for Day-to-Day Business Amid Eli Lilly Challenge
London: Novo Nordisk is changing its day-to-day name to 'Novo', and taking a new approach to company culture as it looks to claw back ground in the fierce obesity drug race, the Danish drugmaker said on Monday.
Novo, which is slated to unveil details on its business strategy during a Capital Markets Day on September 21, will keep 'Novo Nordisk A/S' as its legal name.
The company set out on Monday a new cultural strategy it called "The Novo Way", centred around four principles - customer obsession, competitiveness, clarity, and care and integrity.
The move comes as it faces fierce competition from rival weight-loss drug maker Eli Lilly, investor pressure to deliver new blockbusters, and setbacks to its medicine pipeline.
The company's Copenhagen shares are down nearly 15% this year, even as its oral GLP-1 outpaces Eli Lilly by hundreds of thousands of U.S. prescriptions per week, according to IQVIA data provided by an analyst.
Commercial gains have been overshadowed by pipeline trouble, capped by last week's decision to scrap two late-stage trials for its experimental heart drug ziltivekimab.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.